Mini Reviews in Medicinal Chemistry This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

The Progress of Small Molecule Targeting BCR-ABL in the Treatment of Chronic Myeloid Leukemia
Mini Rev Med Chem. 2023 Oct 6. doi: 10.2174/0113895575218335230926070130. Online ahead of print.ABSTRACTChronic myelogenous leukemia (CML) is a malignant myeloproliferative disease. According to the American Cancer Society's 2021 cancer data report, new cases of CML account for about 15% of all leukemias. CML is generally divided into three stages: chronic phase, accelerated phase, and blast phase. Nearly 90% of patients are diagnosed as a chronic phase. Allogeneic stem cell transplantation and chemotherapeutic drugs, such as interferon IFN-α were used as the earliest treatments for CML. However, they could generate obvio...
Source: Mini Reviews in Medicinal Chemistry - October 19, 2023 Category: Chemistry Authors: Yuan Zhang Xin Wu Xueyan Sun Jun Yang Chang Liu Guotao Tang Xiaoyong Lei Honglin Huang Junmei Peng Peng Source Type: research

Recent Advances in Natural Products with Anti-Leukemia and Anti-Lymphoma Activities
Mini Rev Med Chem. 2023 Oct 6. doi: 10.2174/0113895575258798230927061557. Online ahead of print.ABSTRACTLeukemia and lymphoma are the most common blood cancers, which pose a critical threat to the health of adults and children. The total incidence and mortality rates of both are approximately 6% globally. Compared with the expensive cost of CAR T cell therapy, natural products from animals, plants and microorganisms have the characteristics of wide-range sources and costeffectiveness in the treatment of cancer. Moreover, the drug resistance that emerged in leukemia and lymphoma treatments shows an urgent need for new drugs...
Source: Mini Reviews in Medicinal Chemistry - October 19, 2023 Category: Chemistry Authors: Zhi-Gang Sun Cheng-Jie Yao Inam Ullah Zhu Hailiang Source Type: research

A Comprehensive Review on Chemistry and Biology of Tafamidis in Transthyretin Amyloidosis
Mini Rev Med Chem. 2023 Oct 11. doi: 10.2174/0113895575241556231003055323. Online ahead of print.ABSTRACTTransthyretin amyloid cardiomyopathy and Transthyretin amyloid peripheral neuropathy are progressive disease conditions caused by Transthyretin amyloidosis (ATTR) fibril infiltration in the tissue. Transthyretin (TTR) protein misfolding and amyloid fibril deposits are pathological biomarkers of ATTR-related disorders. There are various treatment strategies targeting different stages in pathophysiology. One such strategy is TTR tetramer stabilization. Recently, a new TTR tetramer stabilizer, tafamidis, has been introduce...
Source: Mini Reviews in Medicinal Chemistry - October 13, 2023 Category: Chemistry Authors: Monali B Patil Piyush Ghode Prashant Joshi Source Type: research

Purinergic Signaling and its Role in the Stem Cell Differentiation
Mini Rev Med Chem. 2023 Oct 11. doi: 10.2174/0113895575261206231003151416. Online ahead of print.ABSTRACTPurinergic signaling is a mechanism in which extracellular purines and pyrimidines interact with specialized cell surface receptors known as purinergic receptors. These receptors are divided into two families of P1 and P2 receptors, each responding to different nucleosides and nucleotides. P1 receptors are activated by adenosine, while P2 receptors are activated by pyrimidine and purines. P2X receptors are ligand-gated ion channels, including seven subunits (P2X1-7). However, P2Y receptors are the G-protein coupled rece...
Source: Mini Reviews in Medicinal Chemistry - October 13, 2023 Category: Chemistry Authors: Sumera Zaib None Areeba Imtiaz Khan Source Type: research

Natural and Synthetic Phosphodiesterase Inhibitors in 2023: an Update on the Impact on Neurological and Psychiatric Conditions
Mini Rev Med Chem. 2023 Oct 4. doi: 10.2174/0113895575267412230926055026. Online ahead of print.ABSTRACTThis Perspective provides an updated overview on the involvement of phosphodiesterase (PDE) isoforms and of the corresponding inhibitors in neurological disorders, including dementia, Parkinson's disease, multiple sclerosis, neuropsychiatric conditions and cerebral ischemia. Particular attention has been dedicated to natural and semi-synthetic compounds. Translation into the clinic of preclinical results, toxicity profile and bioavailability represent the challenging aspects in the development of PDE inhibitors. With the...
Source: Mini Reviews in Medicinal Chemistry - October 11, 2023 Category: Chemistry Source Type: research